We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

25 Jun 2026 - 27 Jun 2026
02 Jul 2026 - 04 Jul 2026
08 Jul 2026 - 10 Jul 2026

Alliance to Develop Drug for Asthma, COPD

By HospiMedica staff writers
Posted on 16 Nov 2004
An agreement to collaborate on commercializing a new drug for asthma and chronic obstructive pulmonary disease (COPD) has been announced by Glenmark Pharmaceuticals S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL, Mumbai, India) and Forest Laboratories, Inc. More...
(New York, NY).

GRC 3886 is a novel, orally available phosphodiesterase 4 (PDE4) inhibitor being developed for chronic COPD and asthma by Glenmark. PDE4 inhibitors target the underlying cause of both COPD and asthma by blocking inflammation through a nonsteroid dependent mechanism. GRC 3886 is now entering phase I clinical trials in the United Kingdom. In preclinical studies, the compound appears to be effective and well tolerated when given at pharmacologic doses.

Forest will develop, register, and commercialize the compound for use in North America, while Glenmark will retain commercialization rights for the rest of the world. Forest will make an upfront payment to Glenmark upon initiation of the agreement, will make other milestones payments, and will earn a royalty on net sales of the product.

"Forest has consistently demonstrated exceptional development, sales, and marketing skills and we are very excited to partner with them on this product,” said Glen Saldanha, M.D., CEO of Glenmark.



Related Links:
Glenmark
Forest

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Desk Aneroid Sphyg
Diagnostix 750D+
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Conceptual schematic of MEND in combination with eCPCs for laryngotracheal reconstruction (Gehret, P., Ali Akbari Ghavimi, S., Dumas, A.A. et al.Nature Communications (2026). DOI: 10.1038/s41467-026-73680-2)

Personalized Cartilage Graft Offers New Option for Infants with Severe Airway Narrowing

Severe subglottic stenosis is a narrowing of the airway below the vocal cords and above the trachea. The condition can leave infants dependent on tracheostomy while awaiting reconstructive surgery to enable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.